Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2024.052985
Journal Menu
Special Issues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

Past Issues

Open Access

ARTICLE

Liver-directed therapies for fibrolamellar carcinoma: A single-center experience

SAM SON1, AKSHAAR BRAHMBHATT1, KEN ZHAO1, BRETT MARINELLI1, JAMES HARDING2, WILLIAM JARNAGIN3, GHASSAN K. ABOU-ALFA2, HOOMAN YARMOHAMMADI1,*
1 Department of Radiology, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10065, USA
2 Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10065, USA
3 Division of Hepatobiliary Surgery, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, NY 10065, USA
* Corresponding Author: HOOMAN YARMOHAMMADI. Email: email

Oncology Research https://doi.org/10.32604/or.2024.052985

Received 21 April 2024; Accepted 31 May 2024; Published online 09 July 2024

Abstract

Background: This article aims to present the single-institution outcomes of patients with Fibrolamellar Carcinoma (FLC) treated with liver-directed therapies (LDT). Methods: In this single-center retrospective study, all patients diagnosed with FLC who underwent LDT were identified. Between July 2012 and July 2023, six patients were identified. One patient was excluded due to bleeding. Demographic and clinical parameters were recorded. Complications within 30 days of the LDT were evaluated. Radiological treatment responses at 1, 6, and 12 months were assessed per mRECIST. Results: A total of five patients, which included three females and two males, were reviewed. Three patients were treated with transarterial hepatic embolization (TAE; n = 3), transarterial radioembolization (TARE; n = 1), and combined TAE + radiofrequency ablation (n = 1). The objective response rate at one month was 80% [CR = 2 (40%), PR = 2 (40%), and SD = 1 (20%)]. At 12 months (n = 4), two patients demonstrated CR (50%) and two demonstrated PR (50%). Overall survival from LDT at five years was 50%. There was no 30-day mortality among this group of patients or any adverse event attributable to the LDT. Conclusion: TAE, TARE, and ablation are safe and effective therapeutic options for FLC. Based on this study and previously published case reports, ablation and TARE yielded the most favorable results.

Keywords

Fibrolamellar carcinoma (FLC); Hepatocellular carcinoma (HCC); Liver-directed therapy (LDT); Transarterial radioembolization (TARE); Hepatic artery embolization

  • 81

    View

  • 7

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link